AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01099618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
Study NCT01036282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Skill Training
Description: Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
Study NCT01036282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT and Social Cognition
Description: Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
Study NCT05227859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
Study NCT03419806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCIG (Duodopa)
Description: Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg.
Study NCT02699437 — intervention group
Intervention type: OTHER
Intervention: Testing for antiphospholipid antibodies
Description: Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
Study NCT05227859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser
Description: GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.
Study NCT05227859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
Study NCT03563430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Recovery Group
Description: Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
Study NCT03563430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Massage with Foam Roller Group
Description: This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
Study NCT03563430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
Study NCT02083744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsychoEducational Support
Study NCT02083744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard Heart Failure Care
Study NCT04124731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus anlotinib
Description: Sintilimab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21
Study NCT04124731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1. Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~2. Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total.
Study NCT04191525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BPL-1 Probiotic capsules
Description: BPL-1 Probiotic 1 capsule/day
Study NCT04191525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo masked with the same presentation as the experimental product 1 capsule/day
Study NCT03654612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
Study NCT04302415 — intervention group
Intervention type: DRUG
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment.
Study NCT02406690 — intervention group
Intervention type: OTHER
Intervention: Estradiol Valerate, Progesterone in Oil, Leuprolide
Description: Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
Study NCT05243498 — intervention group
Intervention type: OTHER
Intervention: Assessment of the Allogenomic Mismatch Score (AMS)
Description: Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
Study NCT01188070 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Educational materials
Study NCT01188070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education
Description: Educational group sessions
Study NCT01188070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education plus physical exercise
Description: Psychoeducation intervention plus an individualized exercise program
Study NCT03779100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT03779100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study NCT01818037 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract surgery
Study NCT00534209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic B7.1/HLA-A1
Description: Dose: At least 4x10\^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
Study NCT00534209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given intradermally
Study NCT02049554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preconception Care Screener
Study NCT01120522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inferior Vena Cava Filter
Description: Inplant of filter in inferior vena cava.
Study NCT01782950 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
Description: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
Study NCT02130895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPP Criteria Decision Support Content
Description: 55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with >=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation.
Study NCT01032330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occlusion treatment
Description: Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
Study NCT02313519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics are prepared in capsule form
Study NCT02313519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose powder
Study NCT04382690 — intervention group
Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions
Study NCT03757052 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Penicillin Skin Testing
Description: Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
Study NCT00739687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-711
Description: 200 mg tablet BID for 9 months.
Study NCT00739687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 200 mg tablet BID for 9 months.
Study NCT00862888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 200mg dose as an oral solution
Study NCT00862888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for oral solution
Study NCT00862888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for tablet
Study NCT00862888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Single oral dose 100 mg tablet
Study NCT00862888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 125 mg dose as an oral solution
Study NCT00862888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 175 mg dose as an oral solution
Study NCT00862888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 20 mg dose as an oral solution
Study NCT01268319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolic Protection Device (EPD)
Description: The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014 steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient.
Study NCT01268319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracoronary Spectroscopy and Ultrasonic Evaluation
Description: This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
Study NCT01268319 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intracoronary Spectroscopy and Ultrasonic Evaluation
Description: This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
Study NCT01268319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty and Stent Implant
Description: The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
Study NCT01268319 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angioplasty and Stent Implant
Description: The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
Study NCT02406703 — intervention group
Intervention type: DRUG
Intervention: Chloroprocaine
Study NCT02406703 — intervention group
Intervention type: DRUG
Intervention: Mepivacaine
Study NCT00770354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS1402
Description: A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
Study NCT02568527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLGA scaffold
Description: Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
Study NCT04545268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days).
Study NCT04545268 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
Study NCT03674229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive information about weight management programs
Study NCT03674229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information about weight management programs
Study NCT03674229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03674229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03674229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone calls from an assigned patient navigator
Study NCT00770354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Daily 2.5 mg oral letrozole tablet
Study NCT04156867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynesys
Description: discectomy with Dynesys
Study NCT05990647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dynamometric tension assessment
Description: Tension dynamometry was carried out using the Back-Check 600 diagnostic complex by Dr.WOLFF® (GmbH, Germany). The dynamometric stress assessment included tasks for flexion and extension of the body. The functional assessment of the abdominal wall muscles was assessed when preparing the patient for surgery (1-10 days before AWR-abdominal wall reconstruction) and 6 months after AWR.
Study NCT05990647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Postural balance
Description: Postural balance was assessed using raster photostereography and baropodometry on the DIERS diagnostic complex by Formetric-4D (GmbH, Germany). When analyzing the topography of the optical field, muscle imbalance is revealed in the form of lateral deviation and inclination of the trunk and pelvis, as well as the values of the angle of kyphosis and lordosis. When conducting baropodometry, the level of displacement of the pressure area on the feet of patients in a static and dynamic position was assessed. Diagnosis of postural balance in patients with incisional ventral hernia was performed a few days before surgical treatment and 6 months after AWR.
Study NCT05990647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of the hernia defect size
Description: Parameters of the hernial defect, including the volume of the hernial sac, the diameter of the hernial orifice, the ratio of hernia volume to the abdominal cavity volume, were performed using preoperative (1-10 days before AWR) multispiral computed tomography on a GE BrightSpeed 16 tomograph (General Electric©, USA)
Study NCT05990647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity of patients
Description: To analyze the physical activity of patients, the measurement of the number of steps was used. The measurements of steps and the amount of distance traveled were carried out using a physical activity monitor - a fitness bracelet MiBAND (China). Measurements were taken 10 days before AWR and within 6 months after AWR.
Study NCT04261517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
Study NCT04529161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet (FMD)
Description: The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
Study NCT04529161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Routinary diet habits
Description: Subjects will follow their routinary eating habits for 6 consecutive months
Study NCT03596060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
Study NCT03596060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be used for introduction in general anesthesia.
Study NCT03596060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be used for introduction in general anesthesia.
Study NCT03596060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirochaine
Description: Chirochaine 0.5% will be used in regional anesthesia.
Study NCT03596060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
Study NCT04622358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-214-02
Description: 1 tablet administered before the breakfast during 7 days
Study NCT04622358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 1 tablet administered before the breakfast during 7 days